Stock traders are buying a high volume of Gilead Sciences call options (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) was the recipient of unusual options trading activity on Monday. Investors acquired 38,115 call options on the stock. This represents an increase of approximately 133% over the average volume of 16,355 call options.

Analysts set new price targets

Several research companies have recently commented on GILD. Morgan Stanley raised its price target on Gilead Sciences shares from $63.00 to $65.00 and gave the stock an “equal weight” rating in a Friday, July 15 research report. Piper Sandler raised her price target on Gilead Sciences shares from $74.00 to $79.00 in a research note on Monday. TheStreet upgraded Gilead Sciences shares from a “c+” rating to a “b-” rating in a Monday, August 15 research note. BMO Capital Markets launched a hedge on Gilead Sciences shares in a Tuesday, June 7 research note. They issued a “hold” rating and a target price of $63.00 on the stock. Finally, Cantor Fitzgerald began covering Gilead Sciences shares in a Tuesday, July 12 report. They issued a “neutral” rating and a price target of $70.00 on the stock. One research analyst rated the stock with a sell rating, nine gave the company a hold rating and five gave the company a buy rating. According to MarketBeat, Gilead Sciences currently has an average rating of “Hold” and a consensus target price of $72.73.

Gilead Sciences stock performance

pixel

A d Legacy search

We are about to witness a huge economic crisis…

We all know the mainstream media will say anything for more viewers and clicks… But people who are distracted by this kind of propaganda are about to be left behind.

NASDAQ GILD traded at $2.97 on Monday, hitting $68.25. The stock had a trading volume of 927,273 shares, compared to an average volume of 8,673,028. The company has a debt ratio of 1.30, a quick ratio of 1.27 and a current ratio of 1, 43. Gilead Sciences has a 12-month low of $57.17 and a 12-month high of $74.12. The company’s 50-day moving average price is $62.73 and its 200-day moving average price is $61.77. The stock has a market capitalization of $85.54 billion, a P/E ratio of 20.81, a price-to-earnings growth ratio of 0.67 and a beta of 0.31.

Gilead Sciences announces dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 29. Shareholders of record on Thursday, September 15 will receive a dividend of $0.73. This represents an annualized dividend of $2.92 and a yield of 4.28%. The ex-dividend date is Wednesday, September 14. Gilead Sciences’ dividend payout ratio (DPR) is 89.02%.

Gilead Sciences Institutional Trading

Major investors have recently been buying and selling shares of the company. Landmark Wealth Management LLC acquired a new stake in shares of Gilead Sciences in the first quarter worth approximately $30,000. Joseph P. Lucia & Associates LLC purchased a new equity stake in Gilead Sciences in Q1 for $25,000. TFO TDC LLC acquired a new stock position in Gilead Sciences in Q1 worth $27,000. Cornerstone Advisory LLC acquired a new stock position in Gilead Sciences in Q4 worth $34,000. Finally, Mystic Asset Management Inc. acquired a new position in Gilead Sciences stock in Q4 worth $33,000. Institutional investors and hedge funds hold 78.58% of the company’s shares.

About Gilead Sciences

(Get a rating)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops and markets drugs in areas of unmet medical need in the United States, Europe and globally. The Company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy and Viread for the treatment of liver disease.

Recommended Stories

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Gilead Sciences, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Gilead Sciences was not on the list.

While Gilead Sciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Comments are closed.